Dignify Therapeutics LLC, a Triangle-based drug development company focused on restoring bladder and bowel control to people with spinal injury, spina bifida, and other neurological conditions, announced today an agreement with ILS to establish a preclinical urodynamics pharmacology laboratory at their facilities in RTP.

Dignify Therapeutics is developing novel pharmaceutical treatments for bladder and bowel dysfunction in people with spinal cord injury, spina bifida, multiple sclerosis, and other neurological conditions.  “An attractive feature for establishing our company in RTP is the availability of state-of-the-art laboratory support services in the area.  ILS has a 29 year history of providing high-quality, well-regulated preclinical facilities that enables entrepreneurs to obtain “critical path data” at a cost that is affordable to early-stage companies,” said Dr. Lesley Marson, a co-founder of Dignify Therapeutics. and an Adjunct Professor in the Department of Urology at UNC.  “ILS’ flexibility, in allowing us to equip the laboratory to meet our highly specialized needs, will allow Dignify’s scientists to continue their innovative, state-of-the-art pharmacology studies of bladder and bowel dysfunction at a level of scientific rigor that is in keeping with the high standards of our team’s earlier published works.”

“At ILS, we understand that early-stage companies require a contract research organization who is an active partner in helping the company obtain preclinical efficacy and safety data to attract funds to carry them into the clinic.  We are very proud that a company with the distinguished scientific reputation of Dignify’s founders has placed their confidence in our facilities and scientific staff,” commented Kevin Causey, Director of Commercial Development at ILS. “Our flexibility reflects our philosophy that early-stage companies are an investment for ILS, for Research Triangle Park, and for patients who benefit from their biomedical advances.”

About Dignify Therapeutics LLC
Founded by a team of serial entrepreneurs who are internationally-recognized scientists and clinicians, Dignify Therapeutics’ mission is to provide safe and effective, practical and convenient, “on-demand” pharmaceutical agents to treat bladder and bowel voiding dysfunctions, using a “repositioning” strategy of drug discovery that the team has successfully implemented multiple times over the last 20 years in the fields of urology and gastroenterology.

About the ILS
Advancing Science, Improving Lives. ILS is a leading life sciences services company that provides research support to federal and commercial clients. Among ILS’ core capabilities are investigative toxicology, genetic toxicology, molecular biology, histopathology, and environmental and information science services. These services are provided to a host of clients, including the National Institute of Environmental Health Sciences, National Toxicology Program, the National Cancer Institute, the U.S. Environmental Protection Agency, the U.S. Army, and numerous clients in the chemical and pharmaceutical markets. Based in Research Triangle Park, NC, ILS was founded by Chairman Dr. Thomas. K. Rao in 1985. For more information please visit http://www.ils-inc.com

 

PRESS CONTACT:
Dignify Therapeutics
Karl Thor, PhD
P.O. Box 13169 – 2 Davis Drive
Research Triangle Park, NC  27709
Phone: 919-371-8138
Email:  [email protected]
Website:  http://dignifytherapeutics.com

ILS
Kevin Causey, MBA
Director of Commercial Development
ILS, Inc./ ILS Genomics
P.O. Box 13501
RTP, NC 27709
919-281-1110
[email protected]
www.ils-inc.com